StreetAlpha.app
Home › Stocks › RANI

Rani Therapeutics Holdings, Inc. (RANI)

$0.51
▼ −11.97%
LAST CLOSE · NOV 20

Rani Therapeutics develops the RaniPill capsule, an oral delivery technology for drugs and biologics that are now often given by injection. It last closed at $0.51 on Nov 20, down 11.97% on the day. The next earnings report for RANI is expected around Thu, Mar 25, 2027, after the close. For the quarter ended Sep 2026, RANI reported EPS of -$0.04 on revenue of $1.7M. Over its last 8 reports the stock moved an average of 8.4% the session after earnings. Over the last 12 months RANI insiders bought $50K of stock on the open market and sold $301, according to SEC Form 4 filings.

AI Auto Pilots
Is RANI in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RANI.

Key Stats

Last 12 months
Results
Revenue
$6.6M
+448.7% vs a year ago
Net income
−$32.5M
−493.0% margin
EPS (diluted)
−$0.07
Free cash flow
−$23.2M
−352.7% margin
Balance sheet
Cash & equivalents
$3.6M
At Sep 30
Shareholder equity
$34.0M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $2.7M$2.7MFY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $1.0M$1.0MFY2024FY2025: $1.6M$1.6MFY2025

From RANI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Mar 25
Estimated date · After the close
Reported EPS
-$0.04
Quarter ended Sep 2026
Year ago EPS
-$0.12
Same quarter last year
Revenue
$1.7M
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.27Dec '24Mar 2025: -$0.22Mar '25Jun 2025: -$0.18Jun '25Sep 2025: -$0.12Sep '25Dec 2025: $0.05Dec '25Mar 2026: -$0.04Mar '26Jun 2026: -$0.04Jun '26Sep 2026: -$0.04Sep '26Latest -$0.04
Revenue by quarter
Dec 2024: $1.0MDec '24Mar 2025: $172,000Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $1.5MDec '25Mar 2026: $1.7MMar '26Jun 2026: $1.7MJun '26Sep 2026: $1.7MSep '26Latest $1.7M
How RANI moved after its last 8 reports
Average move the session after a report ±8.4%
Nov 9, 2026After the close−2.5%
Aug 13, 2026After the close−0.2%
May 15, 2026After the close−10.0%
Mar 26, 2026After the close−24.9%
Nov 6, 2025After the close−11.0%
Aug 7, 2025After the close−0.9%
May 13, 2025After the close+15.6%
Mar 31, 2025After the close−2.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RANIStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on RANI
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RANI

Technical Analysis

RANI · as of the Nov 20 close · updated each morning
Downtrend

The stock is 11% below its 20 day and 33% below its 50 day average. It is 72% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 39). The nearest support is the swing low (Nov 5) at $0.51, and the nearest resistance the Pivot at $0.53.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 10.4%/day
Key levels
$1.8252 week high+256.9%
$0.88200 day average+72.5%
$0.74100 day average+45.1%
$0.6850 day average+33.3%
$0.58Swing high (Nov 11)+13.7%
$0.5720 day average+11.8%
$0.56Pivot R1+9.8%
$0.53Pivot+3.9%
$0.51Swing low (Nov 5)+0.0%
$0.51Last close
$0.5052 week low−2.0%
$0.49Pivot S1−3.9%
Indicators
RSI (14)39.22Weak, oversold below 30Neutral
MACD-0.03Above its signal lineBullish
Stochastic52.5Middle of its rangeNeutral
ADX (14)35.7Trending down
Williams %R-94.1Oversold below −80, overbought above −20Oversold
CCI (20)-98.4Oversold below −100, overbought above 100Neutral
Rate of change−6.5%Change over 10 sessionsBearish
ATR (14)$0.05Typical daily range, 10.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RANI

What happened before

See how RANI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RANI usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RANI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RANIHow many large options trades hit RANI, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

RANI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲29 buying vs 20 selling
  • ▲Shares held by funds +2.6%
  • ▲Funds holding +1
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding6867+1.5%
In funds' top 1000–
Held by funds–––
New / increased8 / 2110 / 15+16.0%
Reduced / sold out13 / 714 / 16−33.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RANI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RANI Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$50K2 buys · 2 insiders
Sold$3011 sale · 1 insider
Cluster buy: 2 insiders bought $50K between Jul 17 and Jul 21.
2026-03 sold $3012026-07 bought $50KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jul 21Mir A ImranDirectorBuy36,000$0.69$25K
Jul 17Talat ImranCEOBuy35,000$0.72$25K
Mar 27Alireza JavadiChief Technical OfficerSale386$0.78$301
Oct 23, 2025Mir A ImranDirectorBuy2,083,334$0.61$1.3M
Oct 21, 2025South Cone Investments Limited Partnership10% ownerSale5,923,000$2.65$15.7M
Dec 27, 2024Talat ImranCEOSale8,014$1.41$11K
Every insider buy and sale for RANI over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RANI insider trades →

From SEC Form 4 filings by RANI's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RANI is in one of them and how their past RANI trades turned out.

RANI in the AI portfolios
Loading…

RANI News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RANI in an article yet. Here's the latest on the wider market.

RANI in the news

About Rani Therapeutics Holdings

Rani Therapeutics is a biotherapeutics company based in San Jose, California. It is developing the RaniPill capsule, a delivery technology designed to let drugs and biologics such as antibodies and peptides be taken orally instead of by injection. The company is advancing its own oral drug candidates and is seeking partnerships with biopharmaceutical companies to use its technology. Its intended customers include patients, physicians, and healthcare systems, and it has no approved products for sale yet.

Headquarters
Fremont, CA